Descrizione business
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants.
Consiglio di amministrazione & Consiglio di sorveglianza
| CEO |
| Naoki Okamura |
| Consiglio di amministrazione |
| Atsushi Kitamura, Katsuyoshi Sugita, Yoshitsugu Shitaka, Tadaaki Taniguchi, Hideki Shima, Claus Zieler, Adam Pearson, Catherine Levitt, Nick Eshkenazi |
| Consiglio di sorveglianza |
| Kenji Yasukawa, Naoki Okamura, Katsuyoshi Sugita, Takashi Tanaka, Eriko Sakurai, Masahiro Miyazaki, Yoichi Ohno, Raita Takahashi, Mika Nakayama, Rie Akiyama, Tomoko Aramaki |
Dati aziendali
| Name: |
Astellas Pharma Inc. |
| Indirizzo: |
2-5-1, Nihonbashi-Honcho,Chuo-Ku, Tokyo 103-8411 |
| Telefono: |
+81-3-3244-3000 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://www.astellas.com/en/ |
| Industria: |
Healthcare |
| Settore: |
Pharmaceutical Industry |
| Sub settore: |
- |
| Fine dell'anno finanziario: |
31/03 |
| Flottante libero: |
- |
| Data dell'IPO: |
- |
Rapporti con gli investitori
| Name: |
- |
| IR telefono: |
+81-3-3244-3202 |
| IR Fax: |
- |
| IR e-mail: |
-
|
